Propargyl compounds

Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The drug is taken by mouth.

chemical compound

chemical compound

Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

Pinazepam (marketed under the brand name Domar and Duna) is a benzodiazepine drug. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

functional group

Prallethrin is a pyrethroid insecticide and mosquito repellent.

Imiprothrin is a synthetic pyrethroid insecticide. It is an ingredient in some commercial and consumer insecticide products for indoor use. It has low acute toxicity to humans through the inhalation and dermal routes, but to insects it acts as a neurotoxin causing paralysis. It is effective against cockroaches, waterbugs, ants, silverfish, crickets and spiders, among others.

chemical compound

Propargite (IUPAC name 2-(4-tert-butylphenoxy)cyclohexyl prop-2-yne-1-sulfonate, trade names Mitex, Omite and Comite) is a pesticide used to kill mites (an acaricide). It acts through inhibition of mitochondrial ATP synthase, and is in IRAC group 12C. Symptoms of excessive exposure are eye and skin irritation, and possibly sensitization. It is highly toxic to amphibians, fish, and zooplankton, as well as having potential carcinogenity.

Pargyline, sold under the brand name Eutonyl among others, is a monoamine oxidase inhibitor (MAOI) medication which has been used to treat hypertension (high blood pressure) but is no longer marketed. It has also been studied as an antidepressant, but was never licensed for use in the treatment of depression. The drug is taken by mouth.

Hexapropymate (brand names Modirax, Merinax, Lunamin) is a hypnotic/sedative. It has effects similar to those of barbiturates and was used in the 1970s-1980s in the treatment of insomnia before being replaced with newer drugs with improved safety profiles.

Talsaclidine (WAL-2014) is a non-selective muscarinic acetylcholine receptor agonist which acts as a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes. It was under development for the treatment of Alzheimer's disease but showed only modest or poor efficacy in rhesus monkeys and humans, respectively, perhaps due to an array of dose-limiting side effects including increased heart rate and blood pressure, increased salivation, urinary frequency and burning upon urination, increased lacrimation and nasal secretion, abnormal accommodation, heartburn, upset stomach

Pargolol is a beta adrenergic receptor antagonist.

MDPL, also known as '3,4-methylenedioxy-N-propargylamphetamine or as N-propargyl-MDA', is a lesser-known drug and a substituted amphetamine.

Clorgiline (), or clorgyline (), is a monoamine oxidase inhibitor (MAOI) and investigational antidepressant related to pargyline. Specifically, it is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A). Clorgiline was never marketed, but it has found use in scientific research.

Propargylamine is an organic compound with the formula HC≡CCH2NH2. It is a colorless, odorless liquid that is used as a precursor to other compounds. Propargyl amines are produced by reactions of amines with propargyl halides.

Nabitan (nabutam, benzopyranoperidine, SP-106, Abbott 40656) is a synthetic cannabinoid analog of dronabinol (Δ9-tetrahydrocannabinol) and dimethylheptylpyran. It exhibits antiemetic and analgesic effects, most likely by binding to and activating the CB1 and CB2 cannabinoid receptors, and reduced intraocular pressure in animal tests, making it potentially useful in the treatment of glaucoma.

Ladostigil (developmental code name TV-3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. It was developed from structural modification of rasagiline.